Citations

Clear

633 citation(s) found for "Reid, J".

Agentic AI-Generated vs. Clinician-Authored Hospital Course Narratives for Cardiology Hospitalizations: A Blinded Physician Evaluation
Lee, Eunjung , Harmon, David , Holmes, Jason , Allman, Alexandra E. , Saey, Stephanie , Schlesinger, Reid P , Félix, Iuri Ferreira , Friedman, Paul A , Attia, Zachi I.

Mayo Clinic

Circulation: Population Health and Outcomes | November 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/circoutcomes.126.014472 | PMID 42993583 Get It

Background: Discharge summaries are essential for safe transitions of care, but writing the hospital course narrative is time intensive. Large language models can generate plausible clinical narratives, yet prior approaches often rely on static inputs and remain vulnerable to omissions and factual inconsistencies. Methods: We developed an electronic health record (EHR)-integrated agentic artificial intelligence (AI) system that uses Gemini 2.5 Pro and Model Context Protocol tools to retrieve clinical notes, diagnostic reports, diagnoses, medications, and appointments on demand. In this retrospective, blinded, paired study, 50 inpatient cardiology encounters were randomly selected from admissions July 13 to 27, 2024, at Mayo Clinic, Rochester, Minnesota. Five physicians rated AI-generated and clinician-authored hospital course narratives for each encounter (250 ratings) on 0-to-10 scales for overall quality, clarity, completeness, accuracy, and readability and indicated a preference. The primary outcome was the paired difference in overall quality (linear mixed-effects model with crossed random intercepts for encounter and reviewer). Secondary domains were analyzed similarly with Bonferroni adjustment, and preference with a crossed random-effects logistic model. Results: Clinician-authored narratives were preferred in 132 ratings (52.8%) and AI-generated narratives in 118 (47.2%) (odds ratio for clinician-authored preference, 1.12; 95% CI, 0.71 to 1.78). Overall quality did not differ significantly (mean, 7.27 AI-generated versus 7.42 clinician-authored; difference, -0.15; 95% CI, -0.86 to 0.56; p=0.627). AI-generated narratives were rated higher for clarity (0.36; 95% CI, 0.07 to 0.65) and readability (0.72; 95% CI, 0.20 to 1.24) but lower for completeness (-0.84; 95% CI, -1.36 to -0.32) and accuracy (-0.35; 95% CI, -0.66 to -0.05). After Bonferroni correction, only lower completeness remained significant (adjusted p=0.012). Conclusions: Hospital course narratives generated by the EHR-integrated agentic AI system did not differ significantly from clinician-authored narratives in physician-rated overall quality or preference. Lower completeness supports continued clinician review before use in the medical record.
BET Bromodomain Pan-D1-Biased Inhibitors with Improved Drug-Like Properties and hERG Profiles as Therapies for Inflammatory Liver Injury
Vail, Nora R. , Doskey, Luke C. , Peterson, Elliott , Scholtz, Cole R. , Gallardo‐Macias, Ricardo , Khanal, Shalil , Buhrow, Sarah A. , McPherson, Joseph E., Sepulveda, Tomás I., Zanon, Trina L., Jerez, Sofia, Alexander, Juliana R. , Gurvich, Vadim J. , Reid, Joel M. , Shi, Ke , Aihara, Hideki , Topczewski, Joseph J., Malhi, Harmeet , Shah, Vijay H. , Pomerantz, William C. K. , Tretyakova, Natalia Y. , Shi, Ke, Topczewski, Joseph J.

Mayo Clinic

No container title available | September 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.26434/chemrxiv.15009359/v1 Get It

BET bromodomain inhibitors are efficacious as anti-inflammatory compounds, but clinical translation is hampered by dose-limiting toxicities from non-selective inhibition. We herein report compounds 16 and 26, based on previously reported 4-methyl-1,2,3-triazole-based inhibitor, DW34. 16 has a BRD4 BD1 Ki of 10 nM, and up to 13–38-fold selectivity for BRD4 BD1 over other BD2 domains, and an improved hERG affinity of 4.24 µM over DW34. 26, A biscyclopropyl analog of 16 showed further enhancement of BD1 selectivity over BD2 (26–203-fold), but exhibited more potent hERG inhibition. Compound 16 had improved liver and plasma clearance over DW34, with good biodistribution to the liver, and had an intracellular target-engagement affinity Ki of 92 nM, with reduction of Ccl2, Cxcl1, AST, and ALT in in vitro and in vivo mouse models of liver inflammation. 16 represents a useful lead for treating inflammatory liver diseases, with improved specificity, drug-like properties, and reduced hERG affinity.
Growing public interest and regional disparities of cardiorenal syndrome in the United States
Schlesinger, Reid P., Kashani, Kianoush B., Thongprayoon, Charat, Cheungpasitporn, Wisit, Miao, Jing , Schlesinger, Reid P , Kashani, Kianoush , Thongprayoon, Charat , Cheungpasitporn, Wisit

Mayo Clinic

Frontiers in Digital Health | September 15, 2026 | Volume: 8 | Issue: No issue available | Pages: No page available

10.3389/fdgth.2026.1803510 | PMID 42812421 Get It

Background Public awareness and regional engagement with cardiorenal syndrome (CRS) remain poorly understood. We examined temporal trends and geographic patterns of U.S. public interest in CRS and their relationship with disease burden. Methods Google Trends™ data (2004–2025) annual relative search interest (RSI) for CRS. CRS-related mortality was derived from CDC WONDER (2007–2020) using hypertensive heart and chronic kidney disease deaths. Temporal trends were assessed via augmented Dickey-Fuller tests and linear regression. Associations between RSI and mortality were evaluated using Pearson correlation, AR(1) modeling, first-difference, and cumulative change analysis. State-level correlations were examined with and without adjustment for income, education, and insurance coverage. Results Both RSI and mortality exhibited strong non-stationary upward trend ( p = 0.98 and 0.42). Raw data showed a strong correlation analysis (r = 0.79, p = 0.001); but first-differenced year-over-year changes were not significant (r = −0.36, p = 0.23), consistent with AR(1) modeling ( β =1.58, p = 0.11). Cumulative changes remained strongly correlated (r = 0.80, p = 0.001), indicating parallel long-term trajectories. Findings were consistent with varying ICD-10 code definitions for CRS-related mortality. Geographically, RSI was highest in West Virginia and lowest in Texas and Georgia. State-level RSI showed no correlation with age-adjusted mortality, both unadjusted (r = −0.09, p = 0.52) and after adjustment for median income, educational, and insurance coverage ( β =0.03, p = 0.75). Conclusion Public interest in CRS has grown in parallel with mortality, reflecting its increasing epidemiological relevance. However, the lack of geographic correlation between search interest and mortality—even after socioeconomic adjustment—suggests awareness gaps and highlights opportunities for targeted education and resource allocation.
Longitudinal single-cell and spatial transcriptomics reveals intratumor heterogeneity, therapeutic response, and comparative value of canine marginal zone lymphoma
Walker, Grace E., Macchietto, Marissa, Reid, Kelly, Burt, Lauren E., Winter, Amber, Pracht, Sara, Buettner, Michelle, Penza, Velia , Yung, Caitlin, Dicovitsky, Rose, Kuzmik, Alana, Vallera, Daniel A. , Demos-Davies, Kimberly, Seelig, Davis , Borgatti, Antonella , Henson, Mike, Feiock, Caitlin, Modiano, Jaime F. , Naik, Shruthi, Sarver, Aaron L. , Treeful, Amy E. , Macchietto, Marissa , Pracht, Sara, Dicovitsky, Rose, Kuzmik, Alana R., Demos-Davies, Kimberly , Naik, Shruthi

Mayo Clinic

No container title available | September 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.10.750253 | PMID 42779884 Get It

Diffuse B-cell lymphomas are the most prevalent canine hematologic malignancies, and their clinical presentation resembles that of human B-cell non-Hodgkin lymphomas (NHLs). However, a lack of a clear subtyping framework perpetuates imprecise treatment approaches that fail to address mechanisms of therapy resistance. Here, we employed deep phenotyping via serial sampling and longitudinal transcriptomics to evaluate intratumoral composition and therapy response in a 6-year-old neutered male goldendoodle with stage 5A marginal zone lymphoma (MZL). Following sequential treatment consisting of a single IV dose of oncolytic vesicular stomatitis virotherapy (VSV) and standard CHOP chemotherapy 30 days later, we performed scRNAseq on seven serial lymph node biopsies and spatial sequencing on a resection taken 10 days post-VSV treatment. B cells (>90%) comprised three transcriptionally distinct and temporally stable subpopulations, with specific copy number profiles and robust spatial organization despite disrupted lymph node architecture. Analysis across subpopulations revealed downregulation of the quiescence program including KLF2, suggesting similarity to KLF2-deficient human MZL. While VSV successfully reached target B cells, downstream transcriptional responses were predominantly localized to the T-cell compartment. T cells (≤6%) showed increased proliferation and upregulation of cytotoxicity markers post-VSV administration, enriching for leukocyte-mediated cytotoxicity pathways consistent with an anti-viral immune response. Ultimately, these results provide an in vivo proof-of-concept for the treatment paradigm in canine lymphoma, while emphasizing the need for improved subtyping frameworks and multidimensional treatment strategies targeting intratumoral heterogeneity.
Diffusion MRI Identifies a Prolonged Pre-WMH Phase in Cerebral Small Vessel Disease
Hu, Mingzhao, Lundt, Emily S. , Kamykowski, Michael G. , Reid, Robert I. , Tm, Therneau, Raghavan, Sheelakumari , Cogswell, Petrice M., Griswold, Michael , Windham, B. Gwen, Petersen, Ronald C. , Graff‐Radford, Jonathan , Vemuri, Prashanthi , Lundt, Emily S , Kamykowski, Michael G , Reid, Robert I , Raghavan, Sheelakumari , Griswold, Michael , Jack, Clifford R , Petersen, Ronald C , Graff-Radford, Jonathan , Vemuri, Prashanthi , Hu, Mingzhao, Cogswell, Petrice M. , Windham, B. Gwen , Jack, Clifford R.

Mayo Clinic

Stroke | July 22, 2026 | Volume: 57 | Issue: 9 | Pages: 2789-2800

10.1161/strokeaha.126.055797 | PMID 42483814 Get It

BACKGROUND: White matter hyperintensities (WMH) are widely used to assess cerebral small vessel disease but reflect late-stage injury. Diffusion magnetic resonance imaging (MRI) biomarkers have been proposed to capture earlier small vessel disease-related microstructural damage but their temporal progression relative to WMH and risk factors associated with progression remain unexplored. METHODS: We identified 2077 participants from the population-based cohort study of the Mayo Clinic Study of Aging in Olmsted County, Minnesota (aged 50–101 years) collected between 05/2005 and 09/2024 with longitudinal neuroimaging. Using multioutput nonlinear mixed-effects models in those with at least 2 fluid-attenuated inversion recovery-MRI and diffusion MRI scans, we characterized the temporal progression of WMH and 4 diffusion MRI biomarkers: fractional anisotropy of the genu of the corpus callosum, peak width of skeletonized mean diffusivity, free water, and Arteriolosclerosis-score, which were automatically estimated. Models incorporated participant-specific time shifts, correlations between biomarkers, and effects of risk factors (sex, education, APOE ε4 status, cardiometabolic conditions). RESULTS: The study population had a mean age of 78 years, 47% were women, 28% were APOE ε4 allele carriers, and 80% were cognitively unimpaired, with an average follow-up of 5.2 years (SD, 4.3 years) for fluid-attenuated inversion recovery-MRI and 4.3 years (SD, 3.9 years) for diffusion MRI. Arteriolosclerosis-score, fractional anisotropy of the genu of the corpus callosum, free water, and peak width of skeletonized mean diffusivity became abnormal in 50% of the study population 16, 12, 10, and 7 years before WMH become abnormal (half-width of CI <1 year), respectively. Global markers (Arteriolosclerosis-score, free water, peak width of skeletonized mean diffusivity, and WMH) were correlated, indicating shared substrates of widespread white matter injury. Fractional anisotropy of the genu of the corpus callosum, a vascular risk microstructural injury biomarker, was weakly coupled with WMH and had an earlier but more linear worsening across adulthood. Cardiometabolic conditions predicted earlier worsening of all biomarkers. Female participants showed earlier WMH, fractional anisotropy of the genu of the corpus callosum, and Arteriolosclerosis-score abnormalities, whereas male participants exhibited earlier peak width of skeletonized mean diffusivity and free water abnormalities. CONCLUSIONS: Diffusion MRI biomarkers were abnormal at least a decade before WMH become abnormal in the population, revealing a prolonged phase of early small vessel disease and highlighting their potential for small vessel disease prevention.
Community-informed development of an in-person forum to promote breast cancer screening and research preparedness in rural and low-socioeconomic status women
Sharma, Pravesh , Imsande, Kaylynn G., Vitriago, Anni, Seibel, Maria, Pritchett, Josh, Rudder, B. de, Tran, Linh T., Larson, Stephanie L., Flock, Carolyn, Murphy, Crystal, Asiedu, Gladys B. , Odedina, Folakemi T., Lynch, Brian, Haddad, Tufia C. , Pritchett, Joshua , Rudder, Bongi, Larson, Stephanie, Patten, Christi , Asiedu, Gladys B , Haddad, Tufia, Sharma, Pravesh , Imsande, Kaylynn G, Larson, Stephanie, Flock, Carolyn R., Murphy, Crystal, Patten, Christi A. , Odedina, Folakemi

Mayo Clinic

Journal of Clinical and Translational Science | July 13, 2026 | Volume: 10 | Issue: 1 | Pages: No page available

10.1017/cts.2026.10788 | PMID 42534402 Get It

Abstract Rural and low-socioeconomic status women face social determinants of health barriers leading to disproportionately low rates of breast cancer screening and markedly reduced participation in clinical trials. To address this gap, we developed the WeCARE (Women’s Engagement for Cancer Awareness, Resources, and Education) intervention using a community-engaged approach. This paper describes how Community Advisory Board feedback informed the development of Mayo Clinic Health System’s WeCARE intervention components. Their input was systematically analyzed using the Consolidated Framework for Implementation Research (CFIR 2.0) to identify determinants of acceptability, appropriateness, and feasibility and to guide actionable refinements to intervention content and delivery.
Comparing Harmonization Approaches for Protocol-Related Variability in Multisite Diffusion MRI Data
Liou, Kenny , Thomopoulos, Sophia I. , Reina, Julio E Villalon, Yoo, Hannah, Shuai, Yuhan , Chehrzadeh, Sasha, Arani, Arvin, Borowski, Bret, Reid, Robert I. , Weiner, Michael, Jahanshad, Neda , Thompson, Paul M., Nir, Talia M., Vemuri, Prashanthi , Jack, Clifford R , Reid, Robert I , Thomopoulos, Sophia I , Reina, Julio E Villalon, Arani, Arvin , Vemuri, Prashanthi , Jack, Clifford R. , Weiner, Michael W , Thompson, Paul M. , Nir, Talia M.

Mayo Clinic

No container title available | July 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.07.737018 | PMID 42465495 Get It

Diffusion MRI (dMRI) enables assessment of white matter microstructural abnormalities in Alzheimer's disease (AD), and multisite datasets enable more robust modeling of non-biological variation that can confound analyses. The Alzheimer's Disease Neuroimaging Initiative (ADNI) includes over 10 dMRI protocols, necessitating robust methods to model protocol-related variability when pooling data. Here, we compared three harmonization approaches: (1) mixed-effects models, (2) ComBat-GAM, and (3) eHarmonize, a reference-based lifespan method. We assessed their ability to reduce protocol-related variability in diffusion tensor imaging fractional anisotropy (FA) and mean diffusivity (MD) while preserving associations with cognitive impairment (CI), and amyloid-beta (Aβ) and tau PET burden in 1,086 ADNI3/4 participants. All approaches yielded more closely aligned FA/MD distributions across protocols. Associations with clinical indicators of CI were highly consistent across approaches, whereas PET associations were less widespread and more variable. Overall, multiple strategies effectively modeled protocol-related variability while preserving AD-related associations.
Operationalizing diffusion magnetic resonance imaging positivity for detection of vascular contributions to impairment and dementia
Hu, Mingzhao, Przybelski, Scott A. , Therneau, Terry M., Wiste, Heather J. , Mester, Carly , Kamykowski, Michael, Reid, Robert I., Machulda, Mary M., Knopman, David S., Petersen, Ronald C., Jack, Clifford R., Graff‐Radford, Jonathan, Vemuri, Prashanthi, Lundt, Emily S. , Mester, Carly T, Hu, Mingzhao, Therneau, Terry M. , Kamykowski, Michael G. , Reid, Robert I. , Machulda, Mary M. , Knopman, David S. , Petersen, Ronald C. , Jack, Clifford R. , Graff‐Radford, Jonathan , Vemuri, Prashanthi

Mayo Clinic

Alzheimer's & Dementia | June 12, 2026 | Volume: 22 | Issue: 6 | Pages: No page available

10.1002/alz.71438 | PMID 42283327 Get It

Abstract INTRODUCTION White matter lesions on fluid‐attenuated inversion recovery magnetic resonance imaging (FLAIR‐MRI) reflect small vessel disease (SVD) and aid in identifying vascular contributions to impairment and dementia (VCID). Emerging diffusion MRI (dMRI) biomarkers are sensitive to early SVD but the lack of validated approaches for defining dMRI abnormality has limited their clinical utility. METHODS In 3934 participants (8749 observations) from a population‐based sample, we classified 9% as vascular cognitive impairment versus not (VCI+/VCI−) using abnormal FLAIR‐MRI and cognitive testing. We evaluated four distinct dMRI positivity criteria and assessed performance in an independent clinical sample. RESULTS The young referent criterion performed best and yielded an estimated prevalence of dMRI positivity aligned with pathology literature. About 40% of the population were dMRI positive, and these individuals had lower baseline cognition and faster longitudinal decline. Cutpoints were validated in an independent clinical sample. DISCUSSION The proposed dMRI abnormality framework can detect VCID and aid in identification of individuals at risk of VCI.
Clinicopathologic characteristics of early‐onset breast cancer among unselected young Black women
Shah, Tiana, Tinker, Rory J., Weidner, Anne , Venton, Lindsay , Roberson, M., Lehmann, Brian D. , Couch, Fergus J., Reid, Sonya, Metcalfe, Kelly , Pal, Tuya, Tinker, Rory J. , Beasley, Heather K , Weidner, Anne , Venton, Lindsay , Metcalfe, Kelly A , Tinker, R J , Beasley, Heather K. , Hu, Chunling , Roberson, Mya L. , Lehmann, Brian David , Couch, Fergus J. , Pal, Tuya

Mayo Clinic

Cancer | June 8, 2026 | Volume: 132 | Issue: 12 | Pages: No page available

10.1002/cncr.70402 | PMID 42252839 Get It

Abstract Background Black women are more likely to develop and die from early‐onset breast cancer. Hereditary breast cancer (HBC) is strongly associated with early age of onset. Accordingly, HBC characteristics in young Black women were evaluated. Methods Black women diagnosed with invasive breast cancer at age 50 years or younger between 2005 and 2018 were recruited through the state cancer registries in Florida and Tennessee. Participants were asked to complete a questionnaire, sign medical records releases, and donate a saliva sample for free genetic testing to identify HBC germline pathogenic or likely pathogenic variant (GPV). Women with sporadic versus hereditary breast cancer were compared, based on age distribution, clinical characteristics, and family cancer history. Results Among 686 participants with confirmed genetic testing, 15.3% had GPVs in breast and/or ovarian cancer predisposition genes, including BRCA1 (7.7%), BRCA2 (4.5%), PALB2 (0.9%), and ATM (0.7%), with 1.5% in other genes. Compared to the sporadic group, triple‐negative breast cancers were overrepresented among BRCA1 carriers (23.6% vs. 75.5%; p < .001), and family history of breast cancer was significantly more frequent among BRCA1 , BRCA2 , and PALB2 carriers (all p < .05). The majority of breast cancers occurred by age 40 years in BRCA1 carriers (52.8%), compared to other genes, where age was more evenly distributed. Conclusion Among unselected young Black women with breast cancer, our findings demonstrate that the highest frequency of HBC GPVs are in BRCA1 , BRCA2, and PALB2, with identification of distinct histopathologic and demographic characteristics across HBC genes, underscoring the critical need for genetic testing in all populations.
A phase 2 clinical trial in progress of (Z)-endoxifen plus goserelin as neoadjuvant therapy in premenopausal women with ER+/HER2– breast cancer (EVANGELINE).
Quay, Steven, ERICKSON, Hayley, Mina, Lida A. , Advani, Pooja , Leon‐Ferre, Roberto A. , Giridhar, Karthik, Flora, Daniel , Jones, Jason M. , Burhow, Sarah, Abramson, Vandana G., Irvin, William Johnson, Ehsani, Sima, Al-Jazayrly, Ghassan, Goetz, M. P., Quay, Steven C. , Suman, Vera J. , Bagegni, Nusayba , Ingle, James N. , Boughey, Judy C. , Burhow, Sarah A., Reid, Joel M. , Abramson, Vandana G. , Irvin, WJ, Khan, Seema A. , Goetz, Matthew P.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.tps655 Get It

TPS655 Background: Early (14-28 day) on-treatment suppression of tumor proliferation during neoadjuvant endocrine therapy (NET) is strongly associated with favorable long-term outcomes in estrogen receptor–positive (ER+) HER2– breast cancer. In premenopausal women, tamoxifen with or without ovarian function suppression (OFS) results in suboptimal Ki-67 suppression compared with aromatase inhibitor + OFS. (Z)-endoxifen (ENDX), the active metabolite of tamoxifen, dually inhibits ER signaling and PKCβ1-mediated AKT activation, supporting its evaluation as an alternative NET strategy in this population. Methods: EVANGELINE (NCT05607004) is an ongoing, multicenter, open-label Phase 2 study evaluating daily 40 mg ENDX plus goserelin administered every 28 days as neoadjuvant therapy in premenopausal women with ER+/HER2–, cT2–3, cN0–1 breast cancer. The primary objective is to determine the proportion of patients with baseline Ki-67 >10% who achieve Ki-67 ≤10% after 4 weeks of therapy. A Simon two-stage design is used to test whether the Week 4 Ki-67 ≤10% rate is at least 65%, with 20 patients enrolled into the first stage and, if promising, another 25 patients enrolled into the second stage (cohort A). A parallel cohort of 20 patients with baseline Ki-67 ≤10% (cohort B) is enrolled to assess objective response rate (ORR) at 24 weeks per RECIST v1.1. Secondary objectives include examining safety and tolerability, residual cancer burden, and PEPI score. Correlative analyses include examining effect of treatment on select tumor and plasma biomarkers. Clinical trial information: NCT05607004 .